A large array of clinically unique disease-modifying therapies (DMTs) is approved for the treatment of multiple sclerosis (MS) in the United States. Competition in this crowded market has intensified with the launch of Ocrevus and Copaxone generics, making treatment choices more complex. The U.S. market is expected to become even more competitive with the potential launch of second-generation follow-on DMTs (e.g., Novartis’s siponimod, Celgene’s ozanimod, Janssen/Acetlion’s ponesimod, Biogen’s BIIB-098) that are poised to offer incremental clinical gains over the next several years, coupled with the entry of oral generics. These evolving dynamics make brand differentiation as well as understanding of drug prescribing patterns and key patient characteristics, including financial burden, ever more critical for current and future players.


  • What is the patient share for Ocrevus, generic versions of Copaxone, orals, and other key therapies?
  • What are the demographic characteristics and clinical profiles of U.S. MS patients on injectables, orals, and infusions?
  • What are the key risk factors, comorbidities, and co-prescribed therapies by patient segment for MS?
  • How do MS patient cohorts compare in care utilization and outcomes (physician visits and other healthcare encounters)?
  • What insurance type and provider do MS patients have?
  • What are the reimbursed and out-of-pocket costs by brand?


Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive Real World Data (RWD) repository.

Table of contents

  • Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Patient Profiler (US)
    • Patient Profiler-Multiple Sclerosis-PPT-June 2018

Author(s): Niyati Khetarpal, Ph.D; Jonathan Searles

"Niyati Khetarpal is a business insights analyst on the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope proteins.”

Jonathan W. Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.

Related Reports

Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

View Details

Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

View Details